(MedPage Today) — Despite missing the primary endpoint, the novel KV7 potassium channel opener azetukalner showed benefit in major depressive disorder (MDD) in the phase II, proof-of-concept, randomized X-NOVA trial.
While the mean reduction…
Source link : https://www.medpagetoday.com/psychiatry/depression/115761
Author :
Publish date : 2025-05-27 15:21:00
Copyright for syndicated content belongs to the linked Source.
